Comparative effectiveness of pegfilgrastim, filgrastim, and sargramostim prophylaxis for neutropenia-related hospitalization: two US retrospective claims analyses
Authors:
- H. J. HenkHHH. J. Henk
- L. BeckerLBL. Becker
- H. TanHTH. Tan
- J. YuJYJ. Yu
- A. KavatiAKA. Kavati
- A. NaeimANA. Naeim
- R. DeeterRDR. Deeter
- R. BarronRBR. Barron
- 10 September 2012
- journal article
- research article
- Published by Taylor & Francis in Journal of Medical Economics
- Vol. 16 (1) , 160-168
Abstract
Few studies have compared the effectiveness of filgrastim (FIL), pegfilgrastim (PEG), and sargramostim (SAR) to reduce the risk of febrile neutropenia (FN) associated with myelosuppressive chemotherapy (M-CT). Two large commercial database analyses were separately conducted to examine the incidence of neutropenia-related and all-cause hospitalizations associated with FIL, PEG, and SAR prophylaxis for patients receiving M-CT for non-Hodgkin lymphoma (NHL), Hodgkin lymphoma, or solid tumors. Separate retrospective US claims database analyses utilized patient data from January 1, 2004 to April 30, 2010 using the HealthCore Integrated Research Database (HIRD(SM)) and January 1, 2001 to August 31, 2009 using OptumInsight's (formerly Ingenix) database. Patients were ≥18 years old and treated with M-CT for NHL, Hodgkin lymphoma, and solid tumors. All identified M-CT cycles with prophylactic (first 5 days of cycle) FIL, PEG, or SAR were included in the analysis. Patterns of administration and incidence rates of all-cause and neutropenia-related hospitalization were examined on a per-cycle basis. In total, 9330 and 8762 patients with cancer, representing 30,264 and 24,215 chemotherapy cycles (28,189 and 22,649 (PEG), 1669 and 1351 (FIL), 406 and 215 (SAR)) from the HIRD(SM) and OptumInsight databases, respectively, were included in the separate database analyses. Both the HIRD(SM) and OptumInsight analysis showed that SAR and FIL prophylaxis had a higher risk of neutropenia-related hospitalization (SAR: OR = 3.48 [95%CI = 2.11, 5.74] and 2.81 [1.62, 4.87]; FIL: 1.78 [1.28, 2.48] and 2.36 [1.82, 3.06], respectively) and all-cause hospitalization (SAR: 2.18 [1.41, 3.36] and 2.41 [1.58, 3.68]; FIL:1.57 [1.25, 1.97] and 1.95 [1.60, 2.38], respectively) vs PEG. Medical claims do not contain information about chemotherapy dose, and hospitalizations were not validated against the patient's chart. In this comparative effectiveness study, use of PEG was associated with a lower risk of neutropenia-related and all-cause hospitalizations compared to use of FIL or SAR prophylaxis.Keywords
This publication has 30 references indexed in Scilit:
- Comparative effectiveness of colony-stimulating factors for febrile neutropenia: a retrospective studyCurrent Medical Research and Opinion, 2010
- Comparison of hospitalization risk and associated costs among patients receiving sargramostim, filgrastim, and pegfilgrastim for chemotherapy‐Induced neutropeniaCancer, 2009
- Cost-effectiveness of pegfilgrastim versus 6-day filgrastim primary prophylaxis in patients with non-Hodgkin's lymphoma receiving CHOP-21 in United StatesCurrent Medical Research and Opinion, 2008
- Granulocyte colony-stimulating factors in the management of chemotherapy-induced neutropenia: evidence based reviewCurrent Opinion in Oncology, 2007
- Granulocyte colony-stimulating factors: finding the right indicationCurrent Opinion in Oncology, 2007
- Population-based Assessment of Hospitalizations for Neutropenia from Chemotherapy in Older Adults with Non-Hodgkin’s Lymphoma (United States)Cancer Causes & Control, 2006
- Mortality, morbidity, and cost associated with febrile neutropenia in adult cancer patientsCancer, 2006
- Incidence, cost, and mortality of neutropenia hospitalization associated with chemotherapyCancer, 2005
- First and Subsequent Cycle Use of Pegfilgrastim Prevents Febrile Neutropenia in Patients With Breast Cancer: A Multicenter, Double-Blind, Placebo-Controlled Phase III StudyJournal of Clinical Oncology, 2005
- Filgrastim in Patients with NeutropeniaDrugs, 2002